Modelling the population cost-effectiveness of current and evidence-based optimal treatment for XXXX .

@entity4697 @entity146 @entity913 @entity8396 @entity1005 @entity148 @entity717 @entity3119
BACKGROUND: The present paper describes a component of a large population cost-effectiveness study that aimed to identify the averted burden and economic efficiency of current and optimal treatment for the major @entity146 . This paper reports on the findings for the @entity148 ( @entity4697 / @entity8396 , @entity913 , generalized @entity148 , @entity1005 and @entity3119 ). METHOD: Outcome was calculated as averted 'years lived with disability' ( @entity717 ), a population summary measure of disability burden. Costs were the direct health care costs in 1997-8 Australian dollars. The cost per @entity717 averted (efficiency) was calculated for those already in contact with the health system for a mental health problem (current care) and for a hypothetical optimal care package of evidence-based treatment for this same group. Data sources included the Australian National Survey of Mental Health and Well-being and published treatment effects and unit costs. RESULTS: Current coverage was around 40% for most disorders with the exception of @entity913 at 21%. Receipt of interventions consistent with evidence-based care ranged from 32% of those in contact with services for @entity913 to 64% for @entity1005 . The cost of this care was estimated at dollar 400 million, resulting in a cost per @entity717 averted ranging from dollar 7761 for generalized @entity148 to dollar 34 389 for @entity4697 / @entity8396 . Under optimal care, costs remained similar but health gains were increased substantially, reducing the cost per @entity717 to < dollar 20 000 for all disorders. CONCLUSIONS: Evidence-based care for @entity148 would produce greater population health gain at a similar cost to that of current care, resulting in a substantial increase in the cost-effectiveness of treatment.
